Patients with cannabinoid hyperemesis syndrome consumed notably more healthcare resources than non-cannabis users, though the differences were not statistically significant across all cost categories in this small study.
Emergency medicine physicians, healthcare economists, cannabis health researchers
CHS patients undergo extensive repeated evaluations before receiving correct diagnosis
What the researchers found
Comparing patients with CHS to those who denied cannabis use, researchers found that CHS patients underwent extensive and repeated evaluations across clinic, emergency department, and inpatient settings, consuming more healthcare dollars overall.
Why it matters
As cannabis legalization spreads and CHS incidence is expected to rise, early recognition through thorough history-taking could prevent unnecessary workups and reduce the financial burden on both patients and the healthcare system.
The numbers in context
Cost differences between CHS and non-CHS groups were noted but not statistically significant across all categories; CHS patients had repeated evaluations in clinic, ED, and inpatient settings.
How the study worked
Retrospective comparison of costs incurred by patients with CHS versus patients without cannabis use across various healthcare settings.
What this study cannot tell us
Small sample size limited statistical power; cost differences were not consistently significant; single-center study; retrospective design.
How to read the evidence
Small retrospective comparison without consistently significant cost differences, providing preliminary evidence only.
When this study was published
Published in 2021.
The bigger picture
The difficulty in diagnosing CHS, which mimics other conditions causing cyclical vomiting, means patients often undergo expensive testing before receiving the correct diagnosis, pointing to a need for better clinical awareness.
Questions still open
- Would standardized CHS screening protocols in emergency departments reduce unnecessary testing? How much could early diagnosis save per patient?
Common questions
What is cannabinoid hyperemesis syndrome?
Why does CHS lead to high healthcare costs?
Read the original research
Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.
Proceedings (Baylor University. Medical Center), 34(6), 654-657
Citation
Sandhu, Gurkaminder; Smith, Steven; Stephenson, Kristen; Jaeger, Victoria; John, Rebekah; Shaver, Courtney; Johnson, Christopher. (2021). Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.. Proceedings (Baylor University. Medical Center), 34(6), 654-657. https://doi.org/10.1080/08998280.2021.1937874
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit